CCL2 and inflammatory bowel disease: The studies of Xiao-Yu Ai confirm that apigenin effectively inhibits inflammatory bowel disease and colitis-associated cancer through decreased levels of the inflammatory cytokines TNF-α, IL-1β, IL-6, MCP-1, and CSF-1 and of COX-2 in tumors [67].